Close Menu
  • Indian Festivals 2026
  • Movie & OTT Releases This Week
  • Entertainment
  • NRI Life
  • Research
  • Advertise with us
Facebook X (Twitter) Instagram YouTube
  • Download Indian Community App
  • Advertise Here
Facebook X (Twitter) Instagram
Indian CommunityIndian Community
Trending
  • The Last Salute Movie Review 2026: An Unmissable Tribute That Soars With Raw MiG-21 Stories
  • Hi Movie Review 2026: Kavin-Nayanthara’s Delightful Rom-Com Is a Refreshing Watch
  • Once More (2026) Movie Review: Arjun Das and Aditi Shankar’s Heartfelt Tamil Romance Is A Beautiful Second-Chance Love Story
  • Babita Singh Reporting Review 2026: A Powerful, Unforgettable Journey Into Courage and Truth
  • Toxic: A Fairy Tale For Grown-Ups 2026 Movie Review— Yash Delivers A Stunning Gangster Spectacle
  • Bindi, Tilak, or Sindoor: Here’s What That Dot on the Forehead Actually Means
  • Bethlehem Kudumba Unit Movie Review 2026: A Heartwarming Onam Blockbuster That Wins Hearts
  • Irumudi Movie Review 2026: Ravi Teja Delivers a Powerful Comeback Performance in Shiva Nirvana’s Emotional Thriller
  • Indian Festivals 2026
  • Entertainment
  • Latest Movie Releases
    • Latest OTT Releases
  • NRI Life
  • India & Culture
  • Health & Wellness
  • Research
Indian CommunityIndian Community
Home » News » Business
Business

AstraZeneca Pharma India’s net profit slips 4 pc in Q1

Indian Community Editorial TeamBy Indian Community Editorial TeamAugust 14, 20252 Mins ReadNo Comments Add us to Google Preferred Sources
AstraZeneca Pharma India’s net profit slips 4 pc in Q1
Share
Facebook Twitter LinkedIn Pinterest Email

Mumbai, Aug 14 (IANS) AstraZeneca Pharma India Limited on Thursday reported a 4.12 per cent decline in net profit for the first quarter (Q1) of FY26, with earnings falling to Rs 55.8 crore from Rs 58.2 crore in the previous quarter (Q4 FY25).

This dip came despite a strong rise in revenue from operations, which grew 9.56 per cent sequentially to Rs 526.3 crore from Rs 480.4 crore, according to its stock exchange filing.

Other income saw a sharp decline of 30.43 per cent, dropping to Rs 11.2 crore from Rs 16.1 crore in Q4 FY25.

However, total income rose 8.23 per cent to Rs 537.5 crore from Rs 496.6 crore, driven by solid operational performance.

Total expenses increased by 12.12 per cent to Rs 462.4 crore, compared to Rs 412.4 crore in the previous quarter, the company stated in its regulatory filing.

Bhavana Agrawal, Chief Financial Officer and Director of the Company, said the strong quarterly performance reflects the power of science-led innovation combined with disciplined execution.

“Each regulatory milestone brings us closer to transforming outcomes for patients living with chronic diseases. We remain focused on expanding our portfolio, strengthening partnerships, and ensuring that breakthrough medicines reach the people who need them most,” she added.

Praveen Rao Akkinepally, Country President and Managing Director, said that delivering consistent growth across therapy areas reaffirms the strength of the company’s “Growth Through Innovation” strategy.

“These results are a testament to what is possible when science and purpose come together,” he noted.

AstraZeneca, a global science-led biopharmaceutical company, focuses on the discovery, development, and commercialisation of prescription medicines, primarily in oncology, cardiovascular, renal and metabolism, respiratory, and rare diseases.

The company operates in over 100 countries, with its medicines used by millions of patients worldwide.

Completing 45 years in India, AstraZeneca Pharma India Limited is headquartered in Bengaluru and employs over 600 people across the country.

–IANS

pk

Add us to Google Preferred Sources
Indian Community Editorial Team

The Indian Community Editorial Team curates, verifies, and publishes stories that matter to Indians worldwide. From culture and community to business and innovation, our mission is to spotlight voices, ideas, and events that bring our global community closer together. Have news or a story to share? Submit it to us at [email protected].

Add A Comment

Piyush Soni: The Chokra Singer’s Journey Back to Music

August 24, 2026

Formula 1: Max Verstappen pens contract extension with Red Bull till 2030

August 20, 2026

Prakash Raj to play revered carnatic music maestro in ‘Jagamae Sangeetham’

August 20, 2026

Three in four occupiers plan to expand their office portfolios in India over next two years

August 20, 2026
  • Facebook
  • Twitter
  • Pinterest
  • Instagram
About Us
  • About Us
  • Contact Us
  • Terms of Service
Corporate
  • Download Indian Community App
  • Advertise Here
Facebook X (Twitter) Instagram
  • About Us
  • Contact Us
  • Terms of Service
© 2026 Designed by CreativeMerchants.

Type above and press Enter to search. Press Esc to cancel.